MoonLake Immunotherapeutics Archives

Home / Posts tagged MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Announces the Full Dataset from Its 24-week MIRA Clinical Trial, Establishing the Nanobody® Sonelokimab As a Highly Promising and Differentiated Therapeutic Solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS) Maintenance treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved HiSCR75 at week 24, increasing the landmark week 12 responses (primary endpoint) by [...]

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

ZUG, Switzerland, June 28 (Korea Bizwire) – MoonLake Immunotherapeutics (Nasdaq:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the pricing on June 27, 2023 of its upsized underwritten public offering of 8,000,000 Class A ordinary shares at a public offering price per share of $50.00. The gross proceeds [...]

MoonLake Immunotherapeutics Achieves Landmark Milestone with Positive Phase 2 Results for Nanobody® Sonelokimab in Hidradenitis Suppurativa

ZUG, Switzerland, June 25 (Korea Bizwire) – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). The MIRA trial (M1095-HS-201), which [...]